【摘要】 目的:本研究旨在探讨不同化疗方案以及患者年龄对化疗诱导停经的影响,为进一步内分泌治疗药物的选择提供依据。方法:回顾性研究绝经前乳腺癌患者接受化疗后月经变化情况,比较不同化疗方案及患者不同年龄段月经状态变化的差异。结果:在103例患者中,蒽环类与紫杉类化疗组的月经变化差异无统计学意义(P=0.719)。在不同年龄组中,大于45岁患者永久性停经者的比例明显高于45岁以下患者(P<0.001)。低龄患者发生停经要晚于高龄患者(P=0.001)。结论:年龄是化疗诱导停经的重要影响因素,小于45岁的患者月经受化疗影响较小,停经多为可逆性,则内分泌治疗不适宜直接选择芳香化酶抑制剂。紫杉类化疗药物并没有比蒽环类药物对月经影响更大。更多还原

【Abstract】 Objective:We aimed to study the influence of chemotherapeutic regimens and aging of breast cancer patients on chemotherapy-induced amenorrhea(CIA) and to guide the further selection of drugs for endocrine therapy.Methods:We retrospectively studied the chemotherapy-induced amenorrhea(CIA) of the premenopausal breast cancer patients and compare the difference in CIA between the patients who received different chemotherapies or at different aging periods.Results:One hundred and three women were followed up.The difference in the rate of CIA was not statistically significant between the women who received anthracycline-based chemotherapy and docetaxel-based chemotherapy(70.6% vs 61.1%,P=0.719).The occurrence rate of CIA was significantly higher in older women(>45 years) than young women(≤45 years,P<0.001).CIA occurred more lately in young women than old women(P=0.001).Conclusion:Age is an important factor for the CIA.Chemotherapy has less influence on the menstruation of younger women(≤45 years) and most amenorrhea is reversible.For these patients aromatase inhibitors are not recommended for adjuvant endocrine therapy.The effect of docetaxel on menstruation is not greater than anthracycline.更多还原